Atlas Trials

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Clinical trial NCT06191887 · RECRUITING

Trial details

NCT number
NCT06191887
Sponsor
Mayo Clinic
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Small Lymphocytic LymphomaRecurrent Transformed Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaRefractory Diffuse Large B-Cell LymphomaRefractory Follicular LymphomaRefractory Mantle Cell Lymphoma
Start date
2024-03-18
Primary completion
2040-12-31
Enrollment
27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.